Pretreated PDX Models
The only PDX bank with over 60% of models derived from patients treated with the latest generation targeted cancer therapies
- Champions Oncology: The Leading Preclinical Oncology CRO
- Explore 700+ Pretreated PDX models from diverse Cancer Types
Clinically Relevant Models
The largest living bank of pretreated PDX models, mirroring today's clinical trial population
Pretreated PDX Models
Established from cancer patients treated with the latest generation therapies
Multi-omic Characterization
Extensive clinical annotations coupled with multi-omic datasets and in vivo responses
Industry's Most Extensive Collection of Biologically Relevant, Pretreated PDX Tumor Models
-
700+ pretreated models across 53 cancer types
-
80% of pretreated models are from advanced/metastatic tumors
-
Unique Model Cohorts: EGFRi, PARPi, KRASi, CDKi, BTKi, MEKi, METi, mTORi, CSF1Ri, BETi, CPi, RTKi and many more
Pretreated PDX Model Indications & Modalities
Available Curated Pretreated Model Cohorts
-
HER2i Pretreated
-
CDK4/6i Pretreated ER+
-
Androgen Deprivation Therapy Resistant
-
Osimertinib Pretreated EGFRm Models
-
Immune Therapy Pretreated Models
-
Immune Therapy Pretreated Resistant Models
-
PARPi Pretreated Models
-
Aromatase Inhibitor Resistant Models
-
Checkpoint Inhibitor (CPi) Immunotherapy Pretreated Models
-
Checkpoint Inhibitor (CPi) Immunotherapy Pretreated Resistant Models
Frequently Asked Questions
What are Pretreated PDX models ?
What are the advantages of Champions' pretreated PDX models ?
Evaluating novel cancer therapies using Champion's biobank of pretreated PDX models offers several benefits, including:
Study Drug Resistance Mechanisms: A robust bank of 700+ pretreated models to investigate how tumors develop resistance to current treatments and identify new targets or strategies to counteract this resistance.
Evaluate Therapeutic Efficacy: Evaluate therapeutic efficacy of your novel therapies by testing them on a bank of pretreated models exposed to the latest therapies such as small molecule inhibitors, chemotherapy, antibodies, immunotherapeutics, and more.
Optimizing your pipeline and discovering new targets: Using pretreated PDX models helps optimize your test agents by understanding molecular interactions between the current line of treatments and cancers and identifying new drug targets, paving the way for more effective second- and third-line therapies.
Reducing Drug Development Costs: Utilizing pretreated PDX models in early drug testing can lower cancer drug development expenses by eliminating ineffective compounds before advancing to costly human clinical trials.
How do I find the most suitable pretreated PDX model for my research ?
You can access Champions’ database for model selection in Lumin:
Navigate to Lumin.bio and request access to Lumin Analytics.
There, you can use Model Select to search our database filtering for the tumor type and pretreatment of your need. You can also filter for in vivo response, molecular characteristics, and patient profile, to make your model selection the most precise and your studies the most successful.